Loading…

ModernaMRNACompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Pioneered mRNA vaccine technology with its COVID-19 shot Spikevax, now developing mRNA vaccines and therapies for flu, RSV and cancer.

Momentum leader 99
Mkt cap
$79.6B
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$2.97B
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-49.9 pp
WACC 10.6%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$196.79
1D-4.8%
1W-20.9%
1M-18.7%
3M+47.6%
6M+309.0%
YTD+567.3%
1Y+694.8%
ATR %9.5%
Beta2.35
52w lowhigh29.9% off high

What Moderna does

Pioneered mRNA vaccine technology with its COVID-19 shot Spikevax, now developing mRNA vaccines and therapies for flu, RSV and cancer.

Has one commercial franchise: COVID shots, sold first under government supply contracts and now in the US mainly through pharmacies and health providers on a seasonal vaccination cycle, so sales swing with take-up. Its newer RSV shot is small by comparison. The company has cut spending to stretch cash while its pipeline matures.

Products and services

  • Spikevax (COVID-19 vaccine)
  • mResvia (RSV vaccine)
  • Pipeline: flu, combination, cancer vaccines

Customers

  • Governments/public health systems
  • Healthcare providers

Where it sits in the supply chain

  • Healthcare
  • Biotechnology
  • mRNA vaccine/therapeutic discovery and…

What could go right

  • Pipeline diversification beyond COVID
  • Cancer vaccine breakthrough potential

What could go wrong

  • Steep decline in COVID vaccine demand/revenue
  • Cash burn as pipeline scales

Moat: narrow (IP / patents, process know-how). A pioneering mRNA platform and manufacturing know-how, though platform advantages face growing competition.

Headquarters: Cambridge, Massachusetts, US · Founded: 2010 · Employees: 4,700

Named competitors

Moderna at a glance

Size Moderna (MRNA) is a United States Health Care company (Biotechnology) with a market value of $79.6B, the 170th largest of 3,085 United States companies the cockpit tracks. Shares closed at $196.79 on 18 Nov 2026.

Performance Over six months the shares gained 309.0%, against +33.9% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 14 in its peer set.

Growth Revenue grew 13.1% over the last twelve months (peer median +8.6%); the operating margin is -116.0% (peer median 30.7%).

Valuation It trades at 31.2× enterprise value to sales against a peer median of 7.3× (most expensive of 14).

Capital Return on invested capital runs 49.9 points below its cost of capital (10.6% WACC).

Credit Moderna has 1 bond outstanding ($3.00B).

Short interest Short interest is 8.2% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

20040060021 May 202621 Aug 202618 Nov 2026MRNA 416Peer median 132
Six months, rebased to 100: Moderna against the median of its 13 peers (local-currency closes).

Moderna financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.52B$1.94B$3.24B$6.84B$19.1B
Revenue growth—-40%-53%-64%—
Gross profit$450M$861M$1.58B$1.53B$13.3B
EBITDA-$2.67B-$2.86B-$3.76B-$3.63B$9.61B
Net income-$2.79B-$2.82B-$3.56B-$4.71B$8.36B
Free cash flow-$1.97B-$2.06B-$4.05B-$3.83B$4.58B
Capital expenditure$259M$202M$1.05B$707M$400M
Total debt$4.23B$1.30B$747M$1.24B$1.20B

Quarterly statements and history in the cockpit →

Moderna competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%-20%0%+20%CSLARGXLONN207940IQVNTRA068270GMAB2269BNTXMRNA6-month return →1-month return →
Up and to the right = strong over both horizons. Moderna is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%+75%0×10×20×30×CSLARGXLONN207940IQVNTRA068270GMABGILDUTHR2269BNTXMRNARevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Moderna is the large dot.

Moderna competitors and peer comparison

Head to head with its named competitors (MRNA vs BNTX vs NVAX vs SAN.PA)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Moderna MRNA$79.6B+309%+13%-116%31.2×n/a
BioNTech SE Sponsored ADR BNTX$20.6B-8%-21%-61%1.9×n/a
Novavax NVAX$1.31B-14%-61%-17%2.4×n/a
Sanofi SAN.PA$114B+13%+15%27%2.6×-4.8%
GSK GSK.L$97.9B-3%+4%25%2.8×-0.1%

How Moderna compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Moderna against its 13 peers (data as of 18 Nov 2026)
MeasureMRNAPeer medianRank in peer set
1-month return-18.7%+1.6%2nd lowest of 14
6-month return+309.0%+33.9%highest of 14
Distance from 52-week high-29.9%-11.4%4th lowest of 14
Revenue growth (TTM)+13.1%+8.6%6th highest of 14
Operating margin-116.0%30.7%lowest of 14
EV / Sales31.2×7.3×most expensive of 14
ROIC minus cost of capital-49.9 pp+3.9 pplowest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Moderna MRNAUnited States$79.6B+309%+13%-116%31.2×n/an/a
CSL CSL.AXAustralia$63.7B+102%-2%26%4.8×6.8%+11.0%
argenx SE Sponsored ADR ARGXUnited States$59.1B+17%+71%29%10.3×11.7%+151.4%
Lonza LONN.SWSwitzerland$53.9B+36%-11%25%7.8×15.6%+7.7%
Samsung Biologics 207940.KSSouth Korea$48.7B-6%-20%43%14.5×7.0%+31.4%
Iqvia IQVUnited States$42.5B+50%+9%14%3.3×16.8%+7.5%
Natera NTRAUnited States$42.0B+41%+37%-9%14.1×n/an/a
Celltrion 068270.KSSouth Korea$34.9B+12%+40%32%9.0×10.6%+17.6%
Genmab A/S GMAB.CODenmark$30.8B+103%+15%31%8.4×11.6%+19.5%
Gilead Sciences GILDUnited States$210B+30%+7%38%7.3×-2.4%+3.6%
Amgen AMGNUnited States$240B+34%+9%36%7.2×1.6%+7.8%
United Therapeutics UTHRUnited States$24.6B+2%+2%44%7.1×0.3%+16.5%
Wuxi Bio 2269.HKHong Kong$23.1B+35%+22%32%6.7×20.8%+30.2%
BioNTech SE Sponsored ADR BNTXUnited States$20.6B-8%-21%-61%1.9×n/an/a

Moderna bonds and credit

Moderna has 1 bond outstanding with $3.00B face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Moderna's main competitors?
Named competitors: Pfizer/BioNTech (BNTX), Novavax (NVAX), Sanofi (vaccines) (SAN.PA), GSK (vaccines) (GSK.L). The cockpit's measured peer set (industry) also includes CSL (CSL.AX), argenx SE Sponsored ADR (ARGX), Lonza (LONN.SW), Samsung Biologics (207940.KS), Iqvia (IQV), Natera (NTRA).
Is Moderna expensive compared with its peers?
On ev / sales it trades at 31.2× against a peer median of 7.3×, most expensive of 14 in its peer set.
How has Moderna stock performed?
Over six months to 18 Nov 2026 the shares returned +309.0% against +33.9% for the median peer; over one year +694.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.